Key result
Ginsenoside Rg3 plus cyclophosphamide extends survival ~98% versus control in a lung cancer mouse model.
Why the study?
The effectiveness of ginsenoside Rg3 alone or combined with cyclophosphamide on tumor growth and angiogenesis in human lung cancer was evaluated.
Does ginsenoside Rg3 alone or in combination with cyclophosphamide reduce tumor growth and angiogenesis in a mouse model of human lung cancer?
Population
54 female athymic mice transplanted with human lung cancer cells (A549)
Comparison
Ginsenoside Rg3 alone vs cyclophosphamide alone vs ginsenoside Rg3 plus cyclophosphamide vs control
Design
Randomized preclinical study
Follow-up
18 days plus survival time
Authors
Loading...
Hypothesis-generating in lung cancer models; human trials needed before any clinical consideration.
Does ginsenoside Rg3 alone or in combination with cyclophosphamide reduce tumor growth and angiogenesis in a mouse model of human lung cancer?
Effect estimate: Life elongation rate 98.2%
Absolute Event Rate: 27.22% vs 13.59%
p-value: p=<0.01
Ginsenoside Rg3, alone or combined with cyclophosphamide, inhibits tumor growth and angiogenesis and improves survival in a mouse model of lung cancer.
Li et al. (2011) studied Lung cancer (n=54). Ginsenoside Rg3 and cyclophosphamide vs. Saline (control) was evaluated on Survival time (days) (Life elongation rate 98.2%, p=<0.01). Ginsenoside Rg3 combined with cyclophosphamide significantly prolonged survival time in a mouse model of lung cancer compared to control (27.22 vs 13.59 days, p<0.01).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: